Lomustine 1 of 1

Indication	Glioma					
Treatment	Palliative					
Intent						
Frequency and	Repeat every 42 days for the maximum of 6 cycles.					
number of						
cycles						
Monitoring	Monitor LFT's, U&E's Glucose and FBC at each cycle.					
Parameters	• If Plts >/=150 and neuts >/=1.5 proceed at full dose.					
pre-treatment	• If neuts >/=1.5 and Plts 100-149 discuss with consultant.					
	If neuts < 1.5 and/or PLT <100 defer chemo.					
	Repeat FBC weekly. If FBC still low after first delay, discuss with consultant and consider					
	dose reduction.					
	Dose reduction should be considered if grade 3 or 4 non-haematological toxicity or					
	repeat appearance of grade 2 (except N&V and alopecia). Delay until resolution of					
	toxicity to ≤ grade 1.					
	Lung function-as clinically indicated.					
	*Dose can be increased to 120mg/m² at consultant's discretion.					
	Hepatic impairment:— d/w consultant					
	Renal impairment:					
	 If CrCl >60ml/min give 100% dose 					
	o 45-60ml/min reduce to 75%					
	o 30-44ml/min reduce to 50%.					
	Not recommended if CrCl <30ml/min.					
References	KMCC proforma BRA-006v1, The North London Cancer Network Dosage Adjustment for					
	Cytotoxics in Hepatic Impairment 2009, The North London Cancer Network Dosage					
	Adjustment for Cytotoxics in Renal Impairment 2009 SPC accessed online 05/11/2019					

NB For funding information, refer to CDF and NICE Drugs Funding List

Repeat every 42 days

Day	Drug	Dose	Route	Administration
1	LOMUSTINE	100mg/m ²	РО	Take as a single dose at night on Day 1
	(CCNU)	(see notes above		ONLY.
		*)		Available as 40mg capsule
	Ondansetron	Ondansetron 8mg PO		Take BD for 3 days.
				Take the first dose 30 minutes before
				taking the Lomustine capsules.
	Domperidone	10mg	PO	Up to TDS PRN. Maximum 30mg day.
				Do not take for more than 7 days continuously.
	Dexamethasone	6mg	PO	OM for 3/7
	Movicol sachet	1 sachet	РО	Take the contents of ONE sachet
				dissolved or mixed with water BD as
				required.

Protocol No	BRA-006	Kent and Medway SACT Protocol Disclaimer: No responsibility will be accepted for the accuracy of this information when used elsewhere.		
Version	V2	Written by	M.Archer	
Supersedes	V1	Checked by	C.Waters	
version			E.Parry	
Date	05/12/19	Authorising consultant (usually NOG Chair)	J.Glendenning	